Benzinga | Jun 2, 2021 04:55PM EDT

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented At ASCO From Phase 1b Trial Of ORIC-101 In Combination With Nab-Paclitaxel

Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations

ORIC-101 plasma concentrations provided excellent target coverage; no evidence of drug-drug interaction with nab-paclitaxel

Translational data showed pharmacodynamic modulation of GR biomarkers and high rates of GR expression in tumor types of interest

Antitumor activity demonstrated across multiple advanced solid tumors in heavily pretreated patients, including those previously treated with a taxane-based therapy

Extended PFS observed in patients with late-line relapsed pancreatic cancer who had previously progressed on or after nab-paclitaxel

Conference call and webcast today at 5:00 p.m. ET